about
Overexpression of angiopoietin-1 reduces doxorubicin-induced apoptosis in cardiomyocytesDiacerein improves left ventricular remodeling and cardiac function by reducing the inflammatory response after myocardial infarctionAngiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure.Cardiomyocyte p65 nuclear factor-κB is necessary for compensatory adaptation to pressure overloadRelationship of TLR2, TLR4 and tissue remodeling in chronic rhinosinusitisPathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both?Extracellular mtDNA activates NF-κB via toll-like receptor 9 and induces cell death in cardiomyocytes.Combined deep microRNA and mRNA sequencing identifies protective transcriptomal signature of enhanced PI3Kα signaling in cardiac hypertrophy.Inhibitory kappa-B kinase-β inhibition prevents adaptive left ventricular hypertrophyCardiomyocyte-specific p65 NF-κB deletion protects the injured heart by preservation of calcium handling.Protein kinase Cε-calcineurin cosignaling downstream of toll-like receptor 4 downregulates fibrosis and induces wound healing gene expression in cardiac myofibroblasts.The role of calpains in myocardial remodelling and heart failure.Murine Myocardial Transcriptome Analysis Reveals a Critical Role of COPS8 in the Gene Expression of Cullin-RING Ligase Substrate Receptors and Redox and Vesicle Trafficking Pathways.Evaluation of Innate Immunity Biomarkers on Admission and at Discharge From an Acute Heart Failure Episode.Cardiac fibroblasts support cardiac inflammation in heart failure.
P2860
Q28395625-E54EC934-09CB-4730-8E5D-B643C48024CFQ28545083-08C63148-BEDD-46BD-B56F-6170B80E3245Q33902466-DDFFF1D3-2B4C-4E21-B4BD-E6E56447EFFFQ34847075-36110F40-55CB-4E28-8ECF-66A76DC59811Q35002059-FDFE3109-DB9A-4F06-B09F-850B4A6D6870Q35406317-1E29DC0B-1B55-49C6-AC24-BE1673862B5AQ35761448-09FD8D5C-CEDC-4033-BB54-10BA25AD42CBQ36013581-398E99E6-9D38-44F1-8172-835F30AEF33AQ36024414-9CB5C964-FAEF-44E2-8441-1E2A46E280EFQ36110312-F2737E97-3C49-4ED6-88C8-D7A9E8CA9B73Q37234808-D28F5F1F-DB4C-4548-BBC4-7DA89A538419Q37546836-16A4F4E6-6893-4C3F-845E-085008D9B642Q37994503-B306CE20-FBCD-49C2-B5DE-1AF447AC3489Q38598847-397323DB-738A-422D-AB5B-03D5706BE1C6Q40481029-23ED9C16-F992-4D96-AE43-3C8050AF8B32Q54196284-2ABC4160-C63B-4504-A69E-1F0FD120D9E0
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Innate immunity and remodelling.
@en
type
label
Innate immunity and remodelling.
@en
prefLabel
Innate immunity and remodelling.
@en
P2860
P1476
Innate immunity and remodelling.
@en
P2093
Guro Valen
P2860
P2888
P356
10.1007/S10741-010-9187-1
P577
2011-01-01T00:00:00Z